On May 12, 2022, the Supreme Court of Canada dismissed an application by Canada RNA Biochemical (C-RNA) for leave to appeal (Docket No. 39994) a decision of the Federal Court of Appeal relating to the refusal of a Natural Health Product (NHP) licence for C-RNA’s oral lumbrokinase capsules (BOLUOKE).
As previously reported, the Federal Court of Appeal did not find any reviewable error in the decision of the Minister of Health (Minister) to refuse granting an NHP licence for BOLUOKE or in the Federal Court’s reasoning in dismissing C-RNA’s application for judicial review of the Minister’s decision.
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Merck’s JANUVIA crystalline monohydrate DHP salt patent found valid
In a patent infringement action brought under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations, in relation to sitagliptin phosphate monohydrate (Merck’s JANUVIA), Justice ...Read More -
Competition Bureau resolves misleading performance claims case
On April 27, 2022, the Competition Bureau announced that it has reached a settlement agreement with NuvoCare Health Sciences Inc and its founder (collectively “NuvoCare”), who were found to have made ...Read More -
Supreme Court of Canada denies Merck leave to appeal from decision upholding strict interpretation of patent listing deadline
Merck sought leave to appeal a decision of the Federal Court of Appeal (2021 FCA 224) affirming a Federal Court decision upholding Health Canada’s refusal to add a patent relating to a formulation of ...Read More